Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy'...
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
